Division of General and Transplant Hepatology, Baylor Regional Transplant Institute, Baylor All Saints Medical Center at Fort Worth, Baylor University Medical Center at Dallas, 1250 8th Avenue, Suite 515, Fort Worth, TX 76104, USA.
Clin Liver Dis. 2011 May;15(2):297-306, vii-x. doi: 10.1016/j.cld.2011.03.012.
Early diagnosis of hepatocellular carcinoma (HCC) has a significant impact on survival by implementation of effective treatment strategies, including hepatic resection, locoregional ablative therapy, and liver transplantation. The use of serum tumor markers and biopsy are particularly important for diagnosis of small hepatic lesions with atypical features on imaging studies. α-Fetoprotein remains the most frequently used tumor marker for the diagnosis of HCC. The development of novel serum biomarkers for HCC, identification of molecular markers for tissue immunohistochemistry, and emergence of new diagnostic techniques such as proteomic profiling may improve the early detection rate of HCC in the future.
早期诊断肝细胞癌 (HCC) 通过实施有效的治疗策略对生存有重要影响，包括肝切除术、局部消融治疗和肝移植。对于影像学检查表现不典型的小肝病变，血清肿瘤标志物和活检的应用尤其重要。甲胎蛋白仍然是诊断 HCC 最常用的肿瘤标志物。新型 HCC 血清生物标志物的开发、组织免疫组织化学的分子标志物的鉴定以及新的诊断技术如蛋白质组谱分析的出现，可能会提高 HCC 的早期检出率。
